Bronchiectasis

Prior to being diagnosed with bronchiectasis, many patients reported living with symptoms for multiple years, according to results published in European Respiratory Journal.

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.

Fewer patients with bronchiectasis vs. COPD had at least one cardiovascular comorbidity/risk factor, according to results published in Respiratory Medicine.

BOSTON — In a sample of 114 adults with bronchiectasis, 46.5% received a score that indicated impaired swallow function, according to a presentation at the CHEST Annual Meeting.

Among Chinese adults with bronchiectasis and exacerbations in the past year, 24-week dipeptidylpeptidase-1 inhibitor HSK31858 lowered exacerbation incidence, according to a poster at the European Respiratory Society International Congress.

Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and hospitalization within 2 years of diagnosis, according to results published in BMC Pulmonary Medicine.

Adults with bronchiectasis had high total annual health care costs, and the cost of hospitalization was a major contributor to this amount, according to findings published in CHEST.

Patients with non-cystic fibrosis bronchiectasis experienced less FEV1 and FVC decline and had improved quality of life with 52-week once-daily brensocatib vs. placebo, according to findings presented at the World Bronchiectasis Conference.

The odds for symptom resolution after a 14-day antibiotic treatment for nonsevere exacerbation of bronchiectasis increased among Indigenous children and children with low cough scores, according to results published in CHEST.

Among patients with non-cystic fibrosis bronchiectasis, once-daily brensocatib for 52 weeks lowered the annualized pulmonary exacerbation rate and was well tolerated, according to topline results from the ASPEN trial.